Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma

March 31st 2025

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

Ivonescimab Shows Significant PFS Improvement Over Pembrolizumab in PD-L1+ NSCLC

March 31st 2025

Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.

The Long-Term Impact of COVID-19 on Oncology Care: A Five-Year Retrospective

March 31st 2025

Experts across specialties reflect on the long-term effects of COVID-19 on several aspects of cancer care.

Neoadjuvant Pembrolizumab Is Safe and Effective in Resectable Stage III/IV Melanoma

March 30th 2025

Single-dose neoadjuvant pembrolizumab was safe with no surgical delays and boosted MPR rates in resectable melanoma.

CHMP Recommends Approval of Subcutaneous Nivolumab in Multiple Solid Tumors

March 28th 2025

Meta: The CHMP has recommended the European approval of subcutaneous nivolumab in solid tumors.

Second- and Third-Generation TKI Combo Therapies Are at the Forefront of Frontline Ph+ ALL Investigations

March 28th 2025

Gregory Roloff, MD, highlights ongoing frontline TKI research in Ph-positive ALL and why he uses a newer-generation TKI over imatinib.

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27th 2025

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas

March 27th 2025

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer

March 27th 2025

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Itolizumab Misses Primary End Point in Acute GVHD but Shows Meaningful Improvements in Other Areas

March 27th 2025

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Blinatumomab Consolidation Prevents B-ALL Relapses and CAR T-Cell Therapy Consolidation May, Too

March 26th 2025

Gregory Roloff, MD, details data on consolidation therapy with blinatumomab or CAR T-cell therapy for B-ALL, and the role of these agents in this setting.

Fellows Present Their Findings on the Breast Cancer Immune Microenvironment and Telehealth Delivery at National Fellows Forum

March 26th 2025

Tess O’Meara, MD, MHS, and Kelsey H. Natsuhara, MD, discuss their presentations from the OncLive National Fellows Forum at SABCS.

Novel Curriculum Aims to Address Burnout and Foster Wellness Among Fellows

March 25th 2025

Thejal Srikumar, MD, MPH, discusses the Yale School of Medicine's unique approach to offering fellows a space to address professional burnout.

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC

March 20th 2025

Monica Chatwal, MD, details new research shedding light on PARP/ARPI combinations in mCRPC, especially in BRCA-mutated and HRR gene–altered populations.

Adjuvant CDK4/6 Inhibitors Lay a Solid Treatment Foundation in HR+, HER2– Breast Cancer

March 19th 2025

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

March 19th 2025

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.

HER2DX Affects Approximately 50% of Treatment Decisions for HER2+ Breast Cancer

March 18th 2025

HER2DX aided in HER2+ breast cancer therapy decisions and the pCR rate was comparable among those who did and did not have HER2DX-driven treatment changes.

Penpulimab Gains NMPA Approval for First-Line Treatment of Recurrent or Metastatic NPC

March 18th 2025

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

FDA Grants Orphan Drug Designation to Bexobrutideg in Waldenström Macroglobulinemia

March 18th 2025

Bexobrutideg received orphan drug designation from the FDA for the treatment of patients with Waldenström macroglobulinemia.

Pamiparib Plus Surufatinib Shows Modest Activity in Platinum-Resistant Ovarian Cancer

March 17th 2025

Pamiparib plus surufatinib showed signals of activity with a largely hematologic adverse effect profile in patients with PARP-pretreated, platinum-resistant ovarian cancer.